个人中心 - 老虎社区

szueyann

IP属地：未知

帖子 · 1,042帖子 · 1,042
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- szueyannszueyann
  ·2021-12-30
  Pls like.
  非常抱歉，此主贴已删除
  3,378 评论
  2
  分享
  举报
- szueyannszueyann
  ·2021-12-30
  Pls like
  Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents
  A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with
  Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents
  2,892 评论
  2
  分享
  举报
- szueyannszueyann
  ·2021-12-30
  Pls like
  ISIG Stock Alert: 7 Things to Know About Red-Hot Insignia Systems
  One of the short-squeeze favorites that’s been absolutely tearing up the market of late is Insignia
  ISIG Stock Alert: 7 Things to Know About Red-Hot Insignia Systems
  3,842 1
  2
  分享
  举报
- szueyannszueyann
  ·2021-12-30
  Pls like
  非常抱歉，此主贴已删除
  3,802 1
  5
  分享
  举报
- szueyannszueyann
  ·2021-12-30
  Pls like
  非常抱歉，此主贴已删除
  3,400 2
  6
  分享
  举报
- szueyannszueyann
  ·2021-12-28
  Like pls
  非常抱歉，此主贴已删除
  3,972 评论
  2
  分享
  举报
- szueyannszueyann
  ·2021-12-28
  Like pls
  3 Best Long-Term Stocks For Investors In 2022
  Summary 2022 promises to be another exciting year for investors. Diversity is the name of the game,
  3 Best Long-Term Stocks For Investors In 2022
  2,613 评论
  1
  分享
  举报
- szueyannszueyann
  ·2021-12-28
  Like pls
  Stock Pickers Are Struggling to Beat the Market
  Some 85% of active U.S. stock funds were on pace to underperform the S&P 500 this year S&P 500 marke
  Stock Pickers Are Struggling to Beat the Market
  2,445 评论
  3
  分享
  举报
- szueyannszueyann
  ·2021-12-27
  Like and comment thanks
  GameStop Is ‘Very Early in Its Transformation.’ Its Stock Could Tumble.
  As this year comes to an end, arguments about whether to buy or sell highflying meme stock GameStop
  GameStop Is ‘Very Early in Its Transformation.’ Its Stock Could Tumble.
  3,289 1
  2
  分享
  举报
- szueyannszueyann
  ·2021-12-27
  Like and comment. Thanks.
  非常抱歉，此主贴已删除
  3,421 1
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3573721781255613","uuid":"3573721781255613","gmtCreate":1610628374184,"gmtModify":1616203186958,"name":"szueyann","pinyin":"szueyann","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":154,"headSize":86,"tweetSize":1042,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692304629,"gmtCreate":1640838672627,"gmtModify":1640838674080,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Pls like.&nbsp;","listText":"Pls like.&nbsp;","text":"Pls like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692304629","repostId":"1189683133","repostType":4,"isVote":1,"tweetType":1,"viewCount":3378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692304850,"gmtCreate":1640838659371,"gmtModify":1640838666035,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692304850","repostId":"1143463942","repostType":4,"repost":{"id":"1143463942","kind":"news","pubTimestamp":1640831989,"share":"https://www.laohu8.com/m/news/1143463942?lang=&edition=full","pubTime":"2021-12-30 10:39","market":"us","language":"en","title":"Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=1143463942","media":"WSJ","summary":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with ","content":"<html><head></head><body><p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.</p><p>The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.</p><p>At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?</p><p>Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.</p><p>“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/391659260599217c12076cea6c888697\" tg-width=\"1007\" tg-height=\"668\" width=\"100%\" height=\"auto\"/><span>The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNAL</span></p><p>The emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.</p><p>Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.</p><p>They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly&amp; Co.’s cancer drug Alimta, based on research by a university professor.</p><p>Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.</p><p>Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/125cd1b51bc213c732cc20b023d56df3\" tg-width=\"1352\" tg-height=\"734\" width=\"100%\" height=\"auto\"/><span>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESS</span></p><p>The market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.</p><p>Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.</p><p>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.</p><p>One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.</p><p>The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/841b456b86547fecd4464e1358e26c20\" tg-width=\"1298\" tg-height=\"684\" width=\"100%\" height=\"auto\"/><span>A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNAL</span></p><p>Moderna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.</p><p>Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.</p><p>Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.</p><p>This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.</p><p>The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3380b351f910af68ef191b100997c93\" tg-width=\"957\" tg-height=\"615\" width=\"100%\" height=\"auto\"/><span>Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWS</span></p><p>A second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.</p><p>Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.</p><p>As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.</p><p>Moderna didn’t respond to a request for comment regarding the patent.</p><p>Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.</p><p>In October 2020, a small San Diego company, Allele Biotechnology &amp; Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.</p><p>Pfizer and BioNTech dispute the claim, and the litigation is pending.</p><p>Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.</p><p>Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.</p><p>A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.</p><p>More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.</p><p>That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.</p><p>A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Invented Covid-19 Vaccines? Drugmakers Battle Over Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented ...</p>\n\n<a href=\"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143463942","content_text":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNALThe emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly& Co.’s cancer drug Alimta, based on research by a university professor.Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESSThe market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNALModerna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWSA second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.Moderna didn’t respond to a request for comment regarding the patent.Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.In October 2020, a small San Diego company, Allele Biotechnology & Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.Pfizer and BioNTech dispute the claim, and the litigation is pending.Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692304996,"gmtCreate":1640838598433,"gmtModify":1640838599877,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692304996","repostId":"1106665007","repostType":4,"repost":{"id":"1106665007","kind":"news","pubTimestamp":1640833702,"share":"https://www.laohu8.com/m/news/1106665007?lang=&edition=full","pubTime":"2021-12-30 11:08","market":"us","language":"en","title":"ISIG Stock Alert: 7 Things to Know About Red-Hot Insignia Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=1106665007","media":"InvestorPlace","summary":"One of the short-squeeze favorites that’s been absolutely tearing up the market of late is Insignia ","content":"<div>\n<p>One of the short-squeeze favorites that’s been absolutely tearing up the market of late is Insignia Systems(NASDAQ:ISIG). Today, ISIG stock is up more than 20%, surging on impressive volume once again...</p>\n\n<a href=\"https://investorplace.com/2021/12/isig-stock-alert-7-things-to-know-about-red-hot-insignia-systems/\">Web Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ISIG Stock Alert: 7 Things to Know About Red-Hot Insignia Systems</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nISIG Stock Alert: 7 Things to Know About Red-Hot Insignia Systems\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 11:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/isig-stock-alert-7-things-to-know-about-red-hot-insignia-systems/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of the short-squeeze favorites that’s been absolutely tearing up the market of late is Insignia Systems(NASDAQ:ISIG). Today, ISIG stock is up more than 20%, surging on impressive volume once again...</p>\n\n<a href=\"https://investorplace.com/2021/12/isig-stock-alert-7-things-to-know-about-red-hot-insignia-systems/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/isig-stock-alert-7-things-to-know-about-red-hot-insignia-systems/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106665007","content_text":"One of the short-squeeze favorites that’s been absolutely tearing up the market of late is Insignia Systems(NASDAQ:ISIG). Today, ISIG stock is up more than 20%, surging on impressive volume once again.This move follows some rather impressive momentum this week. Indeed, Insignia Systems is a stock that has more than doubled since Monday.As we reported yesterday, Insignia Systems is now in the crosshairs of retail investors. This is a stock with a short interest ratio that remains elevated. Currently, this ratio sits at around 62%, an increase from yesterday.Given this stocks’ relatively low float and low price per share, short squeeze enthusiasts have jumped on Insignia Systems as a top short squeeze candidate. Social media interest remains high around Insignia Systems. Indeed, this smaller-cap stock, with a market capitalization of $41 million at the time of writing, is relatively unknown by the masses.That said, for those intrigued by the recent moves in this stock, let’s dive into a few things investors may want to know.What to Know About ISIG StockInsignia Systems is a company providing a suite of marketing solutions for consumer packaged goods brands.This Minneapolis-based company was founded in 1990.Insignia Systems’ products are aimed at retail-focused brands.Accordingly, investors banking on a rebound in retail activity coming out of this pandemic may like how ISIG stock is positioned.Additionally, Insignia Systems provides digital advertising solutions to its clientele.This combination of services has made Insignia Systems an intriguing growth stock for retail investors.Year-to-date, ISIG stock has been a 3-bagger for investors.","news_type":1,"symbols_score_info":{"ISIG":0.9}},"isVote":1,"tweetType":1,"viewCount":3842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692305490,"gmtCreate":1640838579206,"gmtModify":1640838580655,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692305490","repostId":"2195463093","repostType":4,"isVote":1,"tweetType":1,"viewCount":3802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692305659,"gmtCreate":1640838542471,"gmtModify":1640838543950,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/692305659","repostId":"2195466435","repostType":4,"isVote":1,"tweetType":1,"viewCount":3400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696236556,"gmtCreate":1640700511576,"gmtModify":1640700513040,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696236556","repostId":"2194480174","repostType":4,"isVote":1,"tweetType":1,"viewCount":3972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696236646,"gmtCreate":1640700470593,"gmtModify":1640700472039,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696236646","repostId":"1149386026","repostType":4,"repost":{"id":"1149386026","kind":"news","pubTimestamp":1640694214,"share":"https://www.laohu8.com/m/news/1149386026?lang=&edition=full","pubTime":"2021-12-28 20:23","market":"us","language":"en","title":"3 Best Long-Term Stocks For Investors In 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1149386026","media":"Seeking Alpha","summary":"Summary\n\n2022 promises to be another exciting year for investors.\nDiversity is the name of the game,","content":"<p><b>Summary</b></p>\n<ul>\n <li>2022 promises to be another exciting year for investors.</li>\n <li>Diversity is the name of the game, and these long-term picks could provide market-beating returns for years to come.</li>\n <li>Happy New Year, everyone!</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a9e76c4c4780ab466238eb117b49289\" tg-width=\"1536\" tg-height=\"1178\" width=\"100%\" height=\"auto\"><span>vzphotos/iStock Editorial via Getty Images</span></p>\n<p><b>What Are The Best Long-Term Stocks For 2022?</b></p>\n<p>A new year will bring new challenges and opportunities for investors. Inflation, interest rates, bubbles, COVID-19 variants, the FTC, new technologies, transformative companies, record buybacks, high yields, and other variables promise to make this an exciting time. With this in mind, diversity is an integral part of a well-rounded portfolio for long-term investors. For this reason, I have chosen three picks from different baskets and include a rock-solid REIT pick, VICI Properties (VICI), a Big Tech pick, Alphabet (GOOG/GOOGL), and a dividend stalwart selection, AbbVie (ABBV).</p>\n<p><b>VICI Properties</b></p>\n<p>VICI is a real estate investment trust (REIT) with properties dedicated to gaming and entertainment. It has properties nationwide, including on the Las Vegas Strip. VICI was initially formed as a spinoff of Caesars Entertainment (CZR) in 2017. More than 30% of its current exposure is to the Las Vegas Strip, and this will increase with the acquisition of MGM Growth Properties (MGP).</p>\n<p>Banks in the U.S. are required to undergo stress tests if they meet specific requirements. These tests are designed to ensure that they can function in the case of a financial calamity. VICI went through its own ultimate stress test in the Spring of 2020 and passed with flying colors. The entire Las Vegas Strip was shut for a period, and properties around the country were also profoundly affected. VICI's share price cratered during this time.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/af10a5ccc2e464f90377c2ecdc1daef2\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>The company's revenue, however, actually went up. The adjusted funds from operations also increased in 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5ab088ba648174cb1ba043317b320833\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p>Looking at the chart above, one would never suspect a calamity in gaming was going on during this time. VICI actually increased the dividend in Q2 2020.</p>\n<p>VICI is currently yielding a very safe 5%. The dividend has just been raised in Q3 2021 from $0.33 quarterly per share to $0.36. VICI has raised the dividend each year since its inception, and this should continue. VICI reports that 97% of its long-term rental agreements include escalators tied to inflation. When the consumer price index (CPI) rises, so do the rents. In this way, VICI is a 5% yielding inflation hedge with a rising dividend and accretive acquisition closing soon. In short, an excellent pick for long-term investors.</p>\n<p><b>Google</b></p>\n<p>Google is growing revenues prolifically and across multiple segments. The company had a brilliant 2021, and this momentum should carry on into 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/38f55f1ce9052097365fec82389e9484\" tg-width=\"640\" tg-height=\"261\" width=\"100%\" height=\"auto\"><span>Chart created by author with data from Seeking Alpha</span></p>\n<p>As shown, revenue over the trailing twelve months (TTMs) has reached $239 billion, easily surpassing fiscal 2020 revenue of $183 billion. Growth slowed a bit in 2020 as advertisers cut back on spending; however, this came roaring back in 2021.</p>\n<p>In addition, margins are increasing.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18ecf2c9613b853ad984e9bd95e640a9\" tg-width=\"640\" tg-height=\"276\" width=\"100%\" height=\"auto\"><span>Chart created by author with data from Seeking Alpha</span></p>\n<p>Over the TTMs, Google has posted an EBITDA margin of 36%. This is excellent profitability. Much of this can be attributed to increased revenue for cloud services and YouTube. These segments have substantial expansion potential and should serve long-term investors well. News of the FTC cracking down on AWS could be welcome news to Google shareholders.</p>\n<p>Google also has some of the best valuation metrics of the Big Tech giants, as shown below.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b2975bf5e7bc0ec98f52cfc0fda52b63\" tg-width=\"635\" tg-height=\"515\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><b>AbbVie</b></p>\n<p>AbbVie has been an excellent dividend growth stock for many years, and this is likely to continue. Because of the concerns over the Humira franchise patent cliffs, and other potential legislation regarding drug prices, AbbVie often trades at a discount. Investors who watch for dips can be rewarded handsomely. I discussed this in further detail&nbsp;in this previous article.</p>\n<p>Biosimilars for Humira are coming to U.S. markets in 2023. This will likely cut the revenues AbbVie receives from Humira in half in the first year, judging by the results of introducing biosimilars in Europe. AbbVie has made several moves to get ahead of this in recent periods, including developing new drugs, expanding treatment options for existing drugs, and expanding the product line through acquisition. Examples include Rinvoq and the Allergan acquisition. As of Q1 2020, Humira made up over 54% of all revenue for AbbVie. This was down to 36% by Q2 2021, while total revenue rose considerably.</p>\n<p>AbbVie's dividend is safe, with a payout ratio below 50%. It has also been raised for eight consecutive years. The five-year dividend growth rate is near 18%. This makes AbbVie an excellent pick for long-term dividend growth investors.</p>\n<p><b>Bottom Line</b></p>\n<p>VICI, Google, and AbbVie are stellar companies with extremely positive long-term potential. Each provides an investor's portfolio with different exposure and different potential. VICI is a tested gaming giant with a rising dividend and inflation protection. Google is as solid as they come with much upside and more limited risk than some in Big Tech due to the lower valuation. AbbVie is a dividend-producing machine where investors can snag a higher yield based on moderate risks. The three combined can be part of the bedrock of a well-rounded investment portfolio.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Long-Term Stocks For Investors In 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Long-Term Stocks For Investors In 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 20:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4476923-3-best-long-term-stocks-for-investors-in-2022><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\n2022 promises to be another exciting year for investors.\nDiversity is the name of the game, and these long-term picks could provide market-beating returns for years to come.\nHappy New Year, ...</p>\n\n<a href=\"https://seekingalpha.com/article/4476923-3-best-long-term-stocks-for-investors-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOGL":"谷歌A","ABBV":"艾伯维公司","VICI":"Vici Properties","GOOG":"谷歌"},"source_url":"https://seekingalpha.com/article/4476923-3-best-long-term-stocks-for-investors-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149386026","content_text":"Summary\n\n2022 promises to be another exciting year for investors.\nDiversity is the name of the game, and these long-term picks could provide market-beating returns for years to come.\nHappy New Year, everyone!\n\nvzphotos/iStock Editorial via Getty Images\nWhat Are The Best Long-Term Stocks For 2022?\nA new year will bring new challenges and opportunities for investors. Inflation, interest rates, bubbles, COVID-19 variants, the FTC, new technologies, transformative companies, record buybacks, high yields, and other variables promise to make this an exciting time. With this in mind, diversity is an integral part of a well-rounded portfolio for long-term investors. For this reason, I have chosen three picks from different baskets and include a rock-solid REIT pick, VICI Properties (VICI), a Big Tech pick, Alphabet (GOOG/GOOGL), and a dividend stalwart selection, AbbVie (ABBV).\nVICI Properties\nVICI is a real estate investment trust (REIT) with properties dedicated to gaming and entertainment. It has properties nationwide, including on the Las Vegas Strip. VICI was initially formed as a spinoff of Caesars Entertainment (CZR) in 2017. More than 30% of its current exposure is to the Las Vegas Strip, and this will increase with the acquisition of MGM Growth Properties (MGP).\nBanks in the U.S. are required to undergo stress tests if they meet specific requirements. These tests are designed to ensure that they can function in the case of a financial calamity. VICI went through its own ultimate stress test in the Spring of 2020 and passed with flying colors. The entire Las Vegas Strip was shut for a period, and properties around the country were also profoundly affected. VICI's share price cratered during this time.\nData by YCharts\nThe company's revenue, however, actually went up. The adjusted funds from operations also increased in 2020.\nData by YCharts\nLooking at the chart above, one would never suspect a calamity in gaming was going on during this time. VICI actually increased the dividend in Q2 2020.\nVICI is currently yielding a very safe 5%. The dividend has just been raised in Q3 2021 from $0.33 quarterly per share to $0.36. VICI has raised the dividend each year since its inception, and this should continue. VICI reports that 97% of its long-term rental agreements include escalators tied to inflation. When the consumer price index (CPI) rises, so do the rents. In this way, VICI is a 5% yielding inflation hedge with a rising dividend and accretive acquisition closing soon. In short, an excellent pick for long-term investors.\nGoogle\nGoogle is growing revenues prolifically and across multiple segments. The company had a brilliant 2021, and this momentum should carry on into 2022.\nChart created by author with data from Seeking Alpha\nAs shown, revenue over the trailing twelve months (TTMs) has reached $239 billion, easily surpassing fiscal 2020 revenue of $183 billion. Growth slowed a bit in 2020 as advertisers cut back on spending; however, this came roaring back in 2021.\nIn addition, margins are increasing.\nChart created by author with data from Seeking Alpha\nOver the TTMs, Google has posted an EBITDA margin of 36%. This is excellent profitability. Much of this can be attributed to increased revenue for cloud services and YouTube. These segments have substantial expansion potential and should serve long-term investors well. News of the FTC cracking down on AWS could be welcome news to Google shareholders.\nGoogle also has some of the best valuation metrics of the Big Tech giants, as shown below.\nData by YCharts\nAbbVie\nAbbVie has been an excellent dividend growth stock for many years, and this is likely to continue. Because of the concerns over the Humira franchise patent cliffs, and other potential legislation regarding drug prices, AbbVie often trades at a discount. Investors who watch for dips can be rewarded handsomely. I discussed this in further detail in this previous article.\nBiosimilars for Humira are coming to U.S. markets in 2023. This will likely cut the revenues AbbVie receives from Humira in half in the first year, judging by the results of introducing biosimilars in Europe. AbbVie has made several moves to get ahead of this in recent periods, including developing new drugs, expanding treatment options for existing drugs, and expanding the product line through acquisition. Examples include Rinvoq and the Allergan acquisition. As of Q1 2020, Humira made up over 54% of all revenue for AbbVie. This was down to 36% by Q2 2021, while total revenue rose considerably.\nAbbVie's dividend is safe, with a payout ratio below 50%. It has also been raised for eight consecutive years. The five-year dividend growth rate is near 18%. This makes AbbVie an excellent pick for long-term dividend growth investors.\nBottom Line\nVICI, Google, and AbbVie are stellar companies with extremely positive long-term potential. Each provides an investor's portfolio with different exposure and different potential. VICI is a tested gaming giant with a rising dividend and inflation protection. Google is as solid as they come with much upside and more limited risk than some in Big Tech due to the lower valuation. AbbVie is a dividend-producing machine where investors can snag a higher yield based on moderate risks. The three combined can be part of the bedrock of a well-rounded investment portfolio.","news_type":1,"symbols_score_info":{"VICI":0.9,"GOOGL":0.9,"GOOG":0.9,"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":2613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696236180,"gmtCreate":1640700446369,"gmtModify":1640700447869,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696236180","repostId":"1147662871","repostType":4,"repost":{"id":"1147662871","kind":"news","pubTimestamp":1640695160,"share":"https://www.laohu8.com/m/news/1147662871?lang=&edition=full","pubTime":"2021-12-28 20:39","market":"us","language":"en","title":"Stock Pickers Are Struggling to Beat the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1147662871","media":"The Wall Street Journal","summary":"Some 85% of active U.S. stock funds were on pace to underperform the S&P 500 this year\nS&P 500 marke","content":"<p>Some 85% of active U.S. stock funds were on pace to underperform the S&amp;P 500 this year</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6f2dde8009f5db843df7a9e957e722aa\" tg-width=\"1290\" tg-height=\"860\" width=\"100%\" height=\"auto\"><span>S&amp;P 500 market data displayed at the New York Stock Exchange. Many stock pickers find themselves trailing the S&amp;P 500 to close out 2021.</span></p>\n<p>It was supposed to be a stock picker’s market.</p>\n<p>A late 2020 rally by smaller and cheaper stocks, culminating with&nbsp;the meme-stock craze that started in January, raised hopes that active investing would stage a comeback this year. But as 2021 draws to a close, most professional stock pickers find themselves in familiar territory: trailing the benchmark S&amp;P 500 index.</p>\n<p><img src=\"https://static.tigerbbs.com/811079b045586611a94c9e99ab1d2c75\" tg-width=\"440\" tg-height=\"561\" width=\"100%\" height=\"auto\"></p>\n<p>That many money managers were brimming with optimism in January is nothing new, said Craig Lazzara, a managing director at S&amp;P Dow Jones Indices. “Every year, there are a bunch of forecasts typically from active managers describing why this year is going to be a good year—this will be a stock picker’s market,” Mr. Lazzara said.</p>\n<p>But many active stock funds struggle to beat the market in a given year, and 2021 fits the pattern. Some 85% of active U.S. stock funds were on pace to underperform the S&amp;P 500 this year as of Nov. 30, according to&nbsp;Morningstar&nbsp;Direct. In the same period a year ago, 64% of such funds were running behind the S&amp;P 500, according to Morningstar.</p>\n<p>Some of those funds focus on small or midsize companies, and many were on track to beat the benchmark indexes that more closely resemble their investment style, said Robby Greengold, a Morningstar strategist. Small-cap funds, in particular, have had a strong year relative to their benchmarks.</p>\n<p>Keeping pace with the S&amp;P 500, though,was a different matter.</p>\n<p>“Large-cap stocks this year have generally trounced the small-caps,” Mr. Greengold said.</p>\n<p>Active managers had reason to believe this year might be different. Indeed, the U.S. economy’s recovery from the coronavirus slowdown had emboldened investors to snap up stocks they had previously ignored, Mr. Lazzara said. They went looking for bargains, reasoning that most companies would benefit from the economy’s growth—and not just the ones that proved most resilient earlier in the year.</p>\n<p>Cheap stocks, small-caps and energy companies—categories that lagged behind the S&amp;P 500 at the start of the health crisis—vaulted past the index’s performance in fall 2020, according to S&amp;P Dow Jones Indices.</p>\n<p>Their moment didn’t last. By spring 2021, big growth stocks had found their footing and kept it—helping power the S&amp;P 500 to a 28% gain so far this year. The S&amp;P MidCap 400 is up 23%, while the S&amp;P SmallCap 600 has risen 26%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Pickers Are Struggling to Beat the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Pickers Are Struggling to Beat the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/stock-pickers-are-struggling-to-beat-the-market-11640692983?siteid=yhoof2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some 85% of active U.S. stock funds were on pace to underperform the S&P 500 this year\nS&P 500 market data displayed at the New York Stock Exchange. Many stock pickers find themselves trailing the S&P...</p>\n\n<a href=\"https://www.wsj.com/articles/stock-pickers-are-struggling-to-beat-the-market-11640692983?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.wsj.com/articles/stock-pickers-are-struggling-to-beat-the-market-11640692983?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147662871","content_text":"Some 85% of active U.S. stock funds were on pace to underperform the S&P 500 this year\nS&P 500 market data displayed at the New York Stock Exchange. Many stock pickers find themselves trailing the S&P 500 to close out 2021.\nIt was supposed to be a stock picker’s market.\nA late 2020 rally by smaller and cheaper stocks, culminating with the meme-stock craze that started in January, raised hopes that active investing would stage a comeback this year. But as 2021 draws to a close, most professional stock pickers find themselves in familiar territory: trailing the benchmark S&P 500 index.\n\nThat many money managers were brimming with optimism in January is nothing new, said Craig Lazzara, a managing director at S&P Dow Jones Indices. “Every year, there are a bunch of forecasts typically from active managers describing why this year is going to be a good year—this will be a stock picker’s market,” Mr. Lazzara said.\nBut many active stock funds struggle to beat the market in a given year, and 2021 fits the pattern. Some 85% of active U.S. stock funds were on pace to underperform the S&P 500 this year as of Nov. 30, according to Morningstar Direct. In the same period a year ago, 64% of such funds were running behind the S&P 500, according to Morningstar.\nSome of those funds focus on small or midsize companies, and many were on track to beat the benchmark indexes that more closely resemble their investment style, said Robby Greengold, a Morningstar strategist. Small-cap funds, in particular, have had a strong year relative to their benchmarks.\nKeeping pace with the S&P 500, though,was a different matter.\n“Large-cap stocks this year have generally trounced the small-caps,” Mr. Greengold said.\nActive managers had reason to believe this year might be different. Indeed, the U.S. economy’s recovery from the coronavirus slowdown had emboldened investors to snap up stocks they had previously ignored, Mr. Lazzara said. They went looking for bargains, reasoning that most companies would benefit from the economy’s growth—and not just the ones that proved most resilient earlier in the year.\nCheap stocks, small-caps and energy companies—categories that lagged behind the S&P 500 at the start of the health crisis—vaulted past the index’s performance in fall 2020, according to S&P Dow Jones Indices.\nTheir moment didn’t last. By spring 2021, big growth stocks had found their footing and kept it—helping power the S&P 500 to a 28% gain so far this year. The S&P MidCap 400 is up 23%, while the S&P SmallCap 600 has risen 26%.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696387278,"gmtCreate":1640618698293,"gmtModify":1640618699722,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Like and comment thanks&nbsp;","listText":"Like and comment thanks&nbsp;","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696387278","repostId":"1159836216","repostType":4,"repost":{"id":"1159836216","kind":"news","pubTimestamp":1640615243,"share":"https://www.laohu8.com/m/news/1159836216?lang=&edition=full","pubTime":"2021-12-27 22:27","market":"us","language":"en","title":"GameStop Is ‘Very Early in Its Transformation.’ Its Stock Could Tumble.","url":"https://stock-news.laohu8.com/highlight/detail?id=1159836216","media":"Barrons","summary":"As this year comes to an end, arguments about whether to buy or sell highflying meme stock GameStop ","content":"<p>As this year comes to an end, arguments about whether to buy or sell highflying meme stock&nbsp;GameStop&nbsp;haven’t changed. It’s still a question of belief in what the videogame retailer could become versus what it currently is. But trying to quantify the former results in a stock that is worth a fraction of what it is now, according to one analyst.</p>\n<p>GameStop (ticker: GME), the original meme stock, has been one of the best performers this year. Its shares have gained 707% to $152.14 in 2021, easily outpacing the&nbsp;S&amp;P 500’s&nbsp;26% rise and the&nbsp;Dow Jones Industrial Average’s&nbsp;17% gain.</p>\n<p>But the rise hasn’t been driven by how its business is doing. Instead, it became a favorite on social-media platform Reddit, to the point that it “no longer trades on traditional fundamental valuations or metrics, but on retail investors’ sentiment, hope, momentum, and the powers of crowds,” writes Ascendiant analyst Edward Woo.</p>\n<p>That adds to the risks for anyone who might think about shorting the company—remember, shares were trading over $300 as recently as June—but the fundamentals clearly point to weaker returns going ahead, Woo writes. Losses are still large, while sales of software declined 2% year over year during the most recent quarter as purchases continued to transition away from physical disks to downloads. The company hasn’t provided guidance.</p>\n<p>GameStop does, however, have a couple of things going for it. The first is its chairman, Ryan Cohen, who had success with&nbsp;Chewy&nbsp;(CHWY) and has brought in new management to help point the retailer in a new direction. It also has a lot of cash, about $1.4 billion, according to Woo, after selling a bunch of stock. That makes GameStop more like a venture capital investment, one that could branch out into non-fungible tokens, cryptocurrencies, or other businesses. But it’s also a very risky investment. As a result, Woo lowered his target on the stock to $23 from $24 on Monday, down 85% from this past Thursday’s close. The analyst has a Sell rating on the shares.</p>\n<p>“We acknowledge Mr. Cohen’s success and talents and the large cash GameStop now has greatly [increased] the odds that it can pivot to be a successful e-commerce company,” Woo writes. “However, we are still very early in its transformation and investors are likely facing a very high risk/rewards scenario.”</p>\n<p>Not like that has ever stopped anyone.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop Is ‘Very Early in Its Transformation.’ Its Stock Could Tumble.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop Is ‘Very Early in Its Transformation.’ Its Stock Could Tumble.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/gamestop-new-stock-price-target-analyst-51640613653?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As this year comes to an end, arguments about whether to buy or sell highflying meme stock GameStop haven’t changed. It’s still a question of belief in what the videogame retailer could become versus ...</p>\n\n<a href=\"https://www.barrons.com/articles/gamestop-new-stock-price-target-analyst-51640613653?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.barrons.com/articles/gamestop-new-stock-price-target-analyst-51640613653?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159836216","content_text":"As this year comes to an end, arguments about whether to buy or sell highflying meme stock GameStop haven’t changed. It’s still a question of belief in what the videogame retailer could become versus what it currently is. But trying to quantify the former results in a stock that is worth a fraction of what it is now, according to one analyst.\nGameStop (ticker: GME), the original meme stock, has been one of the best performers this year. Its shares have gained 707% to $152.14 in 2021, easily outpacing the S&P 500’s 26% rise and the Dow Jones Industrial Average’s 17% gain.\nBut the rise hasn’t been driven by how its business is doing. Instead, it became a favorite on social-media platform Reddit, to the point that it “no longer trades on traditional fundamental valuations or metrics, but on retail investors’ sentiment, hope, momentum, and the powers of crowds,” writes Ascendiant analyst Edward Woo.\nThat adds to the risks for anyone who might think about shorting the company—remember, shares were trading over $300 as recently as June—but the fundamentals clearly point to weaker returns going ahead, Woo writes. Losses are still large, while sales of software declined 2% year over year during the most recent quarter as purchases continued to transition away from physical disks to downloads. The company hasn’t provided guidance.\nGameStop does, however, have a couple of things going for it. The first is its chairman, Ryan Cohen, who had success with Chewy (CHWY) and has brought in new management to help point the retailer in a new direction. It also has a lot of cash, about $1.4 billion, according to Woo, after selling a bunch of stock. That makes GameStop more like a venture capital investment, one that could branch out into non-fungible tokens, cryptocurrencies, or other businesses. But it’s also a very risky investment. As a result, Woo lowered his target on the stock to $23 from $24 on Monday, down 85% from this past Thursday’s close. The analyst has a Sell rating on the shares.\n“We acknowledge Mr. Cohen’s success and talents and the large cash GameStop now has greatly [increased] the odds that it can pivot to be a successful e-commerce company,” Woo writes. “However, we are still very early in its transformation and investors are likely facing a very high risk/rewards scenario.”\nNot like that has ever stopped anyone.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":3289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696387336,"gmtCreate":1640618675534,"gmtModify":1640618677061,"author":{"id":"3573721781255613","authorId":"3573721781255613","name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573721781255613","idStr":"3573721781255613"},"themes":[],"htmlText":"Like and comment. Thanks.&nbsp;","listText":"Like and comment. Thanks.&nbsp;","text":"Like and comment. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696387336","repostId":"1151032995","repostType":4,"isVote":1,"tweetType":1,"viewCount":3421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}